Transcarent is the latest to join a long list of companies hoping to transform the world of pharmacy benefits and prescription drugs. But its CEO declares its marrying healthcare delivery with easy, affordable access to pharmaceuticals.
Join us for an introduction to the OBGYN-specific EHR designed to adapt to the way OBGYNs specifically work. ModMed Presenters: Dr. Sherling, Chief Medical/Strategy Officer and OBGYN's: Dr. Ecklund, Medical Director & Dr. Spier, Team Lead
September 28, 2022 at Pegasus Park in Dallas is your opportunity to network with over 30 investors (a 6:1 ratio), meet select Employee Benefits Startups, and participate in expert panel discussions around mental health, pharmacy benefits, the cost of healthcare, reaching consumers and the future of digital health.
By Frank Vinluan Monday, September 19, 2022 6:02 PM
Bluebird Bio gene therapy Skysona has won FDA approval, making it the first FDA-approved therapy for cerebral adrenoleukodystrophy, an ultra-rare and fatal neurological disorder. Skysona's regulatory green light follows the August approval of Zynteglo, a Bluebird gene therapy for a rare blood disorder.
By Marissa Plescia Monday, September 19, 2022 5:29 PM
Employers expect healthcare costs to increase 6% next year, up from the 5% increase they are experiencing this year. Respondents don't see this improving down the road either, with 71% saying they anticipate moderate to significant increases over the next three years.
By Marissa Plescia Monday, September 19, 2022 5:13 PM
It is the first LVAD trial to examine five-year outcomes and surpasses a previous Abbott study on HeartMate 3, which recorded a survival time of two years. The device was found to reduce morbidity and mortality, largely because of fewer deaths by stroke, clotting and bleeding.
Zócalo Health, a virtual primary care provider designed for Latino patients, raised $5 million in seed funding. The startup will use the funds to bolster the services it is delivering in California, as well as expand to Texas and Washington before the year ends.
By Frank Vinluan Monday, September 19, 2022 12:18 PM
Liver disease remains the focus of Genfit, despite a high-profile clinical trial failure in the fatty liver disease NASH. The company is building out its pipeline by acquiring Versantis, a clinical-stage biotech whose most advanced drug candidate brings a novel approach to treating a deadly chronic liver disease complication that has no FDA-approved therapies.
Experts think virtual reality (VR) can help address the country's rising levels of pain and anxiety. By flooding the brain with positive signals, VR experiences can act as a drug-free alternative to pain and mental health management — and hospitals across the nation are deploying the technology.
No comments